Clinical efficacy and cost-effectiveness of therapy for chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2016-26-1-73-78
Abstract
A high prevalence and social importance of chronic obstructive pulmonary disease (COPD) contribute to economic burden for healthcare systems in many countries. Annual growth of expenses on management this disease provides a need of cost optimization. According to clinical guidelines, bronchodilators, primarily long-acting beta-2-agonists and anticholinergics, are the optimal maintenance therapy of COPD. A promising current approach to treatment COPD is a combination of these classes of drugs. Foreign pharmacoeconomic studies demonstrated new possibilities to affect clinical outcomes and to reduce expenditures on COPD management while using novel fixed combination of these bronchodilators.
About the Author
A. S. Belevskiy
State Institution «N.I.Pirogov Russian National Research Medical University», Healthcare Ministry of Russia: 1, Ostrovityanova str., Moscow, 117997, Russia
Russian Federation
Russian Federation
MD, Professor of Department of Pulmonology, Faculty of Postgraduate Physician Training, State Institution «N.I.Pirogov Russian National Research Medical University», Healthcare Ministry of Russia; tel.: (495) 963-24-67
References
1. http://www.who.int/respiratory/copd
2. http://ria.ru/society/20141210/1037570497
3. Vorob'ev P.A., Avksent'eva M.V., Borisenko O.V. et al. Clinical economics. Moscow, N'yudiamed; 2008 (in Russian).
4. Krysanov I.S. Cost analysis of chronic obstructive pulmonary disease in Russian Federation. Kachestvennaya klinicheskaya praktika. 2014; 2: 51–56 (in Russian).
5. Wacker M.E., Jörres R.A., Schulz H. et al. COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir. Med. 2016; 111: 39–46.
6. Ehteshami-Afshar S., FitzGerald J.M., Doyle-Waters M.M., Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Intern. J. Tub. Lung Dis. 2016; 20 (1): 11–23.
7. Dahl R., Chung K.F., Buhl R. et al. On behalf of the INVOLVE Study Investigators. Efficacy of a new once-daily, long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65; 473–479.
8. Kornmann O., Dahl R., Centanni S. et al. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. 2011; 37 (2): 273–279.
9. Zyryanov S.K., Zhudenkov K.V. Economic burden of COPD and cost optimization: focus on new long-acting bronchodilators. Prakticheskaya farmakoekonomika. Bronkhopul'monologiya. M.: Izdatel'skiy dom «Remedium». 2012 (in Russian).
10. Zyryanov S.K., Zhudenkov K.V. Pharmacoeconomic evaluation of therapy of chronic obstructive pulmonary disease using anticholinergics as maintenance therapy and during exacerbation. Prakticheskaya farmakoekonomika. 2014; 2: 43–52 (in Russian).
11. Hizava N. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Intern. J. COPD. 2015: 10: 1093–1102.
12. Mollen V.D., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 2012; 21 (1): 101–108.
13. Rossi A., Zanardi E., Poletti V., Cazzola M. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. Intern. J. COPD. 2015: 10: 1383–1392.
14. Bateman E.D., Ferguson G.T. Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.
15. Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1: 51–60.
16. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1: 199–209.
17. Zhong N., Wang C., Zhou X. et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Intern. J. COPD. 2015: 10: 1015–1026.
18. Geitona M., Kousoulakou H., Kalogeropoulou M. et al. Cost-effectiveness analysis of the fixed combination indacaterol/glycopyrronium vs. tiotropium and salmeterol/fluticasone in the management of COPD in Greece. Value Health. 2015; 18 (7): A500.
19. Rutten-van Mölken M.P., Goossens L.M. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012; 30 (4): 271–302.
20. Price D., Keininger D., Costa-Scharplatz M. et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir. Med. 2014; 108 (12): 1786–1793.
21. Asukai Y., Baldwin M., Fonseca T. et al. Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach. Pharmacoeconomics. 2013; 31: 151–161.
22. Ehteshami-Afshar S., FitzGerald J.M., Doyle-Waters M.M., Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Intern. J. Tub. Lung Dis. 2016; 20 (1): 11–23.
Review
For citations:
Belevskiy A.S. Clinical efficacy and cost-effectiveness of therapy for chronic obstructive pulmonary disease. PULMONOLOGIYA. 2016;26(1):73-78. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-1-73-78
Views:
1005
Email this article 